| URN | urn:agi-cas:60-92-4 |
|---|---|
| Total Entities | 0 |
| Connectivity | 4618 |
| Name | cAMP |
| Ariadne Ontology | Biofluids assayable substances |
|---|
| Pathway | Gap Junction Assembly |
|---|---|
| Purine metabolism | |
| CannabinoidR -> AP-1/EGR signaling | |
| SomatostatinR -> ATF1/TP53 signaling | |
| NeuropeptideYR -> ATF/CREB signaling | |
| PTAFR -> AP-1/ATF1/CREB/ERK-SRF signaling | |
| GRM1/5 -> CREB signaling | |
| IL8R -> CREB/EGR signaling | |
| EndothelinRb -> AP-1/CREB/ELK-SRF signaling | |
| ProstaglandinIR -> ATF1/ELK-SRF/CREB signaling | |
| AdrenergicRb -> CREB signaling | |
| TachykininR -> ELK-SRF signaling | |
| VIPR -> CREB/CEBP signaling | |
| AdrenergicRb -> STAT3 signaling | |
| AngiotensinR -> CREB/ELK-SRF/TP53 signaling | |
| DopamineR1 -> CREB/ELK-SRF signaling | |
| SerotoninR4/6/7 -> NR3C signaling | |
| FSHR -> CREB/ELK-SRF/GATA4 signaling | |
| VasopressinR2 -> CREB/ELK-SRF/AP-1/EGR signaling | |
| GlucagonR -> CREB/ELK-SRF/SP1 signaling | |
| ThromboxaneR -> CREB signaling | |
| CholinergicRn -> CREB signaling | |
| Insulin Action | |
| Melanogenesis | |
| Guanylate Cyclase Pathway | |
| Gonadotrope Cell Activation | |
| Axon Guidance | |
| Apoptosis Regulation | |
| Cell Cycle Regulation | |
| Gap Junction Regulation | |
| Atlas of Signaling | |
| Doxorubicin-Induced Cardiotoxicity | |
| Bextra-Induced Ischemic Disease | |
| ROS and RNS in Regulation of Vasoconstriction and Vasodilation | |
| SST Expression Targets | |
| NPY Expression Targets | |
| Dronabinol/Anandamide Expression Targets | |
| Acetylcholine Expression Targets | |
| Thromboxane A2 Expression Targets | |
| Glutamate/Gq Expression Targets | |
| S1P Expression Targets | |
| TAC1 Expression Targets | |
| PGE1 Expression Targets | |
| Epinephrine/Gs Expression Targets | |
| Noradrenaline/Gs Expression Targets | |
| VIP Expression Targets | |
| Dopamine/Gs Expression Targets | |
| GCG Expression Targets | |
| FSHR Expression Targets | |
| AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets | |
| Serotonin/Gs Expression Targets | |
| CXCL1 Expression Targets | |
| CXCL2 Expression Targets | |
| CXCL3 Expression Targets | |
| CXCL5 Expression Targets | |
| CXCL6 Expression Targets | |
| EDN1 Expression Targets | |
| EDN3 Expression Targets | |
| ADCYAP1 Expression Targets | |
| AGT/TP53 Expression Targets | |
| AGT/ELK-SRF Expression Targets | |
| IL1B/PGE2 Expression Targets | |
| AGT/CREB Expression Targets | |
| PAF/Gq -> AP-1/ATF1/CREB/ERK-SRF Expression Targets | |
| estrogen signaling pathway | |
| melanocortin system pathway | |
| corticotropin-releasing hormone signaling pathway | |
| parathyroid hormone signaling pathway | |
| peripheral dopamine signaling pathway | |
| epinephrine signaling pathway via adrenergic receptor beta | |
| epinephrine signaling pathway via adrenergic receptor beta | |
| vasopressin signaling pathway - first | |
| protein kinase A (PKA) signaling pathway | |
| peripheral dopamine signaling pathway | |
| acetylcholine signaling pathway via muscarinic acetylcholine receptor |
| Group | Biofluids assayable substances |
|---|
| Source | ChemIDplus |
|---|
| MedScan ID | 1216634 |
|---|
| Alias | adenosine-3',5'-monophosphoric acid |
|---|---|
| Adenosine 3,5'-cyclic monophosphoric acid | |
| CCRIS 4291 | |
| Adenosine 3',5'-cyclic monophosphate | |
| Acrasin | |
| 6-(6-Amino-9H-purin-9-yl)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-oxide | |
| 3',5'-AMP | |
| Adenosine 3',5'-cyclophosphorate | |
| Adenosine 3',5'-phosphate monohydrate | |
| 3',5'-cyclic AMP | |
| Adenosine 3',5'-cyclophosphoric acid | |
| Adenosine-3',5'-cyclic phosphate | |
| Adenosine 3,5'-cyclic monophosphorate | |
| adenosine-3',5'-monophosphorate | |
| Adenosine 3',5'-monophosphate | |
| adenosine, cyclic 3',5'-(hydrogenphosphate) | |
| Adenosine, cyclic 3',5'-(hydrogen phosphate) | |
| Adenosine cyclic monophosphate | |
| Adenosine 3',5'-cyclophosphate | |
| Adenosine cyclic 3',5'-monophosphate | |
| cAMP | |
| Adenosine 3',5'-phosphate | |
| Adenosine cyclic 3',5'-phosphate | |
| cyclic 3',5'-Adenylic acid | |
| 3',5'-cyclic adenosine monophosphate | |
| (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidine-3-yl)-1,4-anhydro-D-ribitol cyclic 3',5'-(hydrogen phosphate) | |
| cyclic Adenosine 3',5'-phosphate | |
| adenosine-cyclic-phosphoric-acid | |
| BRN 0052645 | |
| c-AMP | |
| 3',5'-AMP sodium salt | |
| cyclic adenylate | |
| Cyclic 3',5'-adenylate | |
| Cyclic 3',5'-AMP sodium salt | |
| cyclic 3',5'-AMP | |
| adenosine-cyclic-phosphate | |
| cyclic Adenosine 3',5'-monophosphate | |
| cyclic adenosine monophosphate | |
| cyclic adenylic acid | |
| cyclic AMP | |
| Cyclic AMP sodium | |
| Cyclic-3',5'-(hydrogen phosphate)adenosine | |
| EINECS 200-492-9 | |
| Formycin cyclic 3',5'-monophosphate | |
| NSC 94017 | |
| Cyclic 3',5'-(hydrogen phosphate)adenosine monosodium salt | |
| adenosine 3', 5'-phosphate | |
| amp,cyclic | |
| 11002-78-1 | |
| 37839-81-9 | |
| 4-26-00-03618 (Beilstein Handbook Reference) | |
| 60-92-4 |
| KEGG ID | C00575 |
|---|
| IUPAC Name | 6-adenin-9-yl-2-hydroxy-2-keto-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol |
|---|---|
| (4aR,6R,7R,7aS)-6-adenin-9-yl-2-hydroxy-2-keto-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol | |
| sodium (4aR,6R,7R,7aS)-6-adenin-9-yl-2-keto-2-oxido-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol |
| InChIKey | IVOMOUWHDPKRLL-UHFFFAOYSA-N |
|---|---|
| IVOMOUWHDPKRLL-KQYNXXCUSA-N | |
| BXJBFCKTIWRKMQ-MCDZGGTQSA-M |
| Rotatable Bond Count | 1 |
|---|
| ChEBI ID | 17489 |
|---|
| CAS ID | 11002-78-1 |
|---|---|
| 60-92-4 | |
| 37839-81-9 | |
| 85187-54-8 | |
| 54532-48-8 |
| Molecular Weight | 329.205941 |
|---|---|
| 351.187771 |
| PubChem SID | 148964 |
|---|---|
| 789944 | |
| 3778229 | |
| 3882616 |
| PubChem CID | 6076 |
|---|---|
| 23669773 | |
| 274 | |
| 216877 |
| XLogP | -2.600000 |
|---|
| Molecular Formula | C10H12N5O6P |
|---|---|
| C10H11N5NaO6P |
| ChemIDplus ID | 000060924 |
|---|
| LinkUrl | http://rgd.mcw.edu/rgdweb/ontology/annot.html?acc_id=CHEBI:17489&species=All |
|---|